Current Funding Opportunities
- April 19: CTRS Pilot Funding Program LOIs due
Applications accepted on a continuous basis for the following funding programs:
- Committee for Pharmaceutical Development
- Pediatric Device Breakthrough Collaborative Funding Program
Community funding opportunities
CTSI manages two funding programs to support community members and organizations interested in developing ideas and partnerships to address health in Minnesota communities.
The program supports the acceleration and scientific progress of projects focusing on products with commercialization potential, such as medical devices, diagnostics, therapeutics, software, or other human health innovations.
Applications due 11:59pm, March 3, 2021
Review period: March - June
Earliest project start date: July 1
Applications due 11:59pm, June 9, 2021
Review period: June - September
Earliest project start date: October 1
Applications due 11:59pm, September 8, 2021
Review period: September - December
Earliest project start date: January 1, 2022
The Translational Research and Career Training (TRACT) program for pre-and post-doctoral scholars (NIH TL1) provides comprehensive, flexible training for a diverse cohort of predoctoral and postdoctoral trainees who are committed to a substantive and impactful career in translational research and team science.
- 2021 letters of intent (LOIs) due March 31
- Full application due April 30
- Award starts August 1
This program provides funding to help University of Minnesota faculty prepare and implement prospective clinical pilot studies.
- April 19: Letter of intent (LOI) due by 5pm (CST).
- May 10 (approximate): Invitations to submit full proposals sent out.
- June 7: Full proposals due by 5pm (CST).
- August 1 (approximate): Stage I awards announced.
The grant program identifies and funds early-stage projects in which the primary goal is to eventually develop a new therapeutic, diagnostic, medical device, or treatment approach. The 2021 RFA is targeted to support the development of innovations that aim to advance health equity and accessibility.
- April 28: Proposals due
- May-June 2021: Review period
- By July 1: Award notification
- August 1: Anticipated award start date
The goal of these programs is to support the development of pediatric health innovations with the ultimate objective of improving pediatric patient outcomes and quality of life.
This funding opportunity is an open program with no deadline.
The goal of the Committee for Pharmaceutical Development (CPD) is to identify, develop, and commercialize pharmaceutical products by forming networks and fostering dialogue between University of Minnesota researchers and industry experts.
N/A (applications accepted on a continuous basis)
Please contact ODAT Assistant Director Sandra Wells at email@example.com with any questions.